Mycenax Biotech Inc. (TPEX:4726)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
29.10
+0.35 (1.22%)
Apr 28, 2026, 1:30 PM CST
-6.13%
Market Cap 5.96B
Revenue (ttm) 740.24M
Net Income (ttm) -448.63M
Shares Out 207.23M
EPS (ttm) -2.17
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 247,853
Average Volume 282,811
Open 29.35
Previous Close 28.75
Day's Range 28.55 - 29.35
52-Week Range 28.55 - 41.75
Beta 0.59
RSI 33.82
Earnings Date Feb 26, 2026

About Mycenax Biotech

Mycenax Biotech Inc. provides biopharmaceutical services and solutions for drug development and production in Taiwan. The company’s services include program evaluation/confirmation, cell line development and construction, process development technology platforms, drug characterization analysis, establishment of testing methods, and PIC/S GMP drug production. It offers plasmid DNA, antibody-drug conjugates, cell and gene therapy, and exosomes products and services. The company was founded in 2001 and is headquartered in Zhubei, Taiwan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Employees 387
Stock Exchange Taipei Exchange
Ticker Symbol 4726
Full Company Profile

Financial Performance

In 2025, Mycenax Biotech's revenue was 740.24 million, an increase of 8.23% compared to the previous year's 683.92 million. Losses were -448.63 million, -3.96% less than in 2024.

Financial Statements

News

There is no news available yet.